Half-Year 2022 Financial and Clinical Trials Update

TNKase / Activase Global sales CHFbn CER growth -10% Regional sales CER growth US -10% 0.8 0.7 0.6 0.5 0.4 0.3 0.2 International +1% 0.1 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 559m • US: Sales impacted by COVID-19 and purchasing patterns CER-Constant Exchange Rates Roche 183

View entire presentation